×
Successful management of a pregnant woman with COVID-19 and multiple severe complications.
https://doi.org/10.1136/bcr-2021-243594
BMJ Case Reports; Aldika Akbar MI, Gumilar KE et. al.

Sep 18th, 2021 - We report a case of a 36-year-old gravida 2 para 1 woman at 38 weeks of gestation. A caesarean section was performed for severe pre-eclampsia, intrauterine growth restriction and oligohydramnios. The patient suffered postoperative bleeding, and exploratory laparotomy was performed. Uterine atonia, Couvelaire uterus and left adnexal haematoma were found, requiring a supracervical hysterectomy. A...

Deep learning identifies synergistic drug combinations for treating COVID-19.
https://doi.org/10.1073/pnas.2105070118
Proceedings of the National Academy of Sciences of the Un... Jin W, Stokes JM et. al.

Sep 17th, 2021 - Effective treatments for COVID-19 are urgently needed. However, discovering single-agent therapies with activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been challenging. Combination therapies play an important role in antiviral therapies, due to their improved efficacy and reduced toxicity. Recent approaches have applied deep learning to identify synergistic dr...

Protocol for the economic evaluation of COVID-19 pandemic response policies.
https://doi.org/10.1136/bmjopen-2021-051503
BMJ Open; Chua BWB, Huynh VA et. al.

Sep 16th, 2021 - Several treatment options are available for COVID-19 to date. However, the use of a combination of non-pharmaceutical interventions (NPIs) is necessary for jurisdictions to contain its spread. Although the implementation cost of NPIs may be low from the healthcare system perspective, it can be costly when considering the indirect costs from the societal perspective. COVID-19 vaccination campaig...

Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.
https://www.ncbi.nlm.nih.gov/pubmed/34523893
American Family Physician; Odeti S, Yellepeddi VK

Sep 16th, 2021 - Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients.|2021|Odeti S,Yellepeddi VK,|

Variation in clinical characteristics, outcomes, and mortality of hospitalized patients...
https://doi.org/10.1136/jim-2021-001876
Journal of Investigative Medicine : the Official Publicat... Mughal MS, Kaur IP et. al.

Sep 15th, 2021 - As of February 2, 2021, the USA has 26,431,799 reported COVID-19 cases with 446,744 deaths. A high mortality rate (15%-40%) was reported among hospitalized patients with COVID-19 during the first wave of the pandemic. However, data regarding variation in COVID-19-related mortality and severity of illness among hospitalized patients with COVID-19 are heterogeneous. In this retrospective single-c...

Changing Trends in Mortality Among Solid Organ Transplant Recipients Hospitalized for C...
https://doi.org/10.1111/ajt.16840
American Journal of Transplantation : Official Journal Of... Heldman MR, Kates OS et. al.

Sep 14th, 2021 - Mortality among patients hospitalized for Covid-19 has declined over the course of the pandemic. Mortality trends specifically in solid organ transplant recipients (SOTR) are unknown. Using data from a multicenter registry of SOTR hospitalized for Covid-19, we compared 28-day mortality between early 2020 (3/1/20-6/19/20) and late 2020 (6/20/20-12/31/20). Multivariable logistic regression was us...

Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Po...
https://doi.org/10.1055/a-1467-5828
Drug Research; Banerjee A, Kanwar M et. al.

Sep 14th, 2021 - Replication of SARS-CoV-2 depends on viral RNA-dependent RNA-polymerase (RdRp). Remdesivir, the broad-spectrum RdRp inhibitor acts as nucleoside-analogues (NAs). Remdesivir has initially been repurposed as a promising drug against SARS-CoV-2 infection with some health hazards like liver damage, allergic reaction, low blood-pressure, and breathing-shortness, throat-swelling. In comparison, theaf...

Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic.
https://doi.org/10.1159/000518440
Pharmacology Taha HR, Keewan N et. al.

Sep 14th, 2021 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the etiology of COVID-19 pandemic, resulted in significant harm to the affected countries in every aspect of life. The virus infected over 139 million patients and resulted in over 2.9 million deaths until April 16, 2021. New variants of this virus were identified that spread rapidly worldwide. Remdesivir, a prodrug of adenosine ...

Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 an...
https://doi.org/10.1124/molpharm.121.000333
Molecular Pharmacology; Miller SR, McGrath ME et. al.

Sep 11th, 2021 - Equilibrative nucleoside transporters (ENTs) are present at the blood-testis barrier (BTB), where they can facilitate antiviral drug disposition to eliminate a sanctuary site for viruses detectable in semen. The purpose of this study was to investigate ENT-drug interactions with three nucleoside analogs remdesivir, molnupiravir and its active metabolite, EIDD-1931 and four non-nucleoside molecu...

COVID-19 infection in the cancer population: a study of emergency department imaging ut...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423077
Emergency Radiology; Vos D, Smith DA et. al.

Sep 9th, 2021 - To analyze emergency department (ED) computerized tomography (CT) utilization in cancer patients with coronavirus disease 2019 (COVID-19). A retrospective chart review was performed to identify cancer patients who received COVID-19 diagnosis within the single healthcare system and presented to the ED within 30 days of COVID-19 positive date between May 1 and December 31, 2020. In our 61 patient...

Structural Understanding of SARS-CoV-2 Drug Targets, Active Site Contour Map Analysis a...
https://doi.org/10.2174/1874467214666210906125959
Current Molecular Pharmacology; Selvaraj C, Dinesh DC et. al.

Sep 8th, 2021 - The most iconic word of the year 2020 is 'COVID-19', the shortened name for coronavirus disease 2019. The pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is responsible for multiple worldwide lockdowns, an economic crisis, and a substantial increase in hospitalizations for viral pneumonia along with respiratory failure and multiorgan dysfunctions. Recently, the...

Prospective Study of Policies and Use of Therapies for COVID-19 Amongst Australian Heal...
https://doi.org/10.1111/imj.15510
Internal Medicine Journal; Smith EL, Gwee A et. al.

Sep 8th, 2021 - The COVID-19 pandemic has generated significant debate about how emerging infections can be treated in the absence of evidence-based therapies to combat disease. In particular, the use of off-label therapies outside of a clinical trial setting has been controversial. We aimed to longitudinally study policies and prescribing practices pertaining to therapies for COVID-19 in Australian Health Ser...

Remdesivir-associated bradycardia.
https://doi.org/10.1136/bcr-2021-245289
BMJ Case Reports; Ching PR, Lee C

Sep 5th, 2021 - Remdesivir is an antiviral used for the treatment of COVID-19 requiring hospitalisation. Information on its cardiovascular safety profile is scarce. We report the case of a 37-year-old man with COVID-19 who developed bradycardia after receiving remdesivir. We recommend a baseline ECG for all patients prior to receiving remdesivir and continuous cardiac monitoring during treatment, especially am...

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409066
The Lancet. Respiratory Medicine; Marconi VC, Ramanan AV et. al.

Sep 5th, 2021 - Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory properties. This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19. In this phase 3, double-blind, randomised, placebo-controlled trial, participants were enrolled from 101 centres across 12 countries in Asia, E...

Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized con...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8260560
International Immunopharmacology; Fakharian A, Barati S et. al.

Aug 25th, 2021 - COVID-19, which is a disease caused by the SARS-CoV-2 virus, has spread around the world since late 2019. Studies have found associations between the rising levels of TNF-α and severe COVID-19 cases. Hence, TNF-α blocking can possibly be a favorable intervention in modifying COVID-19. To this end, in order to manage pneumonia caused by COVID-19, adalimumab may potentially be considered as a pot...

Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patie...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312090
Clinical Lymphoma, Myeloma & Leukemia; Hammad M, Shalaby L et. al.

Aug 24th, 2021 - Sufficient data pertaining to the impact of the Coronavirus disease 2019 (COVID-19) on pediatric cancer patients is still lacking. The aim of this prospective study was to describe clinical management and outcomes of COVID-19 in pediatric oncology patients. Conducted between May 1, 2020 and November 30, 2020, this study included 76 pediatric oncology patients with confirmed COVID-19. Remdesivir...

Optimal timing of remdesivir initiation in hospitalized COVID-19 patients administered ...
https://doi.org/10.1093/cid/ciab728
Clinical Infectious Diseases : an Official Publication Of... Wong CKH, Lau KTK et. al.

Aug 23rd, 2021 - Evidence is lacking about any additional benefits of introducing remdesivir on top of dexamethasone, and the optimal timing of initiation. In a territory-wide cohort of 10,445 COVID-19 patients from Hong Kong who were hospitalized between 21st January 2020 and 31st January 2021, 1544 patients had received dexamethasone during hospitalization. Exposure group consisted of patients who had initiat...

Transfusion-related acute lung injury in a COVID-19-positive convalescent plasma recipi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381434
The Journal of International Medical Research; Amrutiya V, Patel R et. al.

Aug 21st, 2021 - We present a case of transfusion-related acute lung injury as a complication of convalescent plasma transfusion in a patient who presented with COVID-19-related severe acute respiratory syndrome. Despite treatment with tocilizumab, remdesivir, and intravenous steroids, worsening dyspnea prompted adjunctive treatment with convalescent plasma. Two hours after completion of the plasma transfusion,...

Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected ped...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426849
Journal of Medical Virology; Boshier FAT, Pang J et. al.

Aug 21st, 2021 - Detailed information on intrahost viral evolution in SARS-CoV-2 with and without treatment is limited. Sequential viral loads and deep sequencing of SARS-CoV-2 from the upper respiratory tract of nine hospitalized children, three of whom were treated with remdesivir, revealed that remdesivir treatment suppressed viral load in one patient but not in a second infected with an identical strain wit...

Remdesivir and Mortality in Patients with COVID-19.
https://doi.org/10.1093/cid/ciab698
Clinical Infectious Diseases : an Official Publication Of... Diaz GA, Christensen AB et. al.

Aug 20th, 2021 - The impact of remdesivir (RDV) on COVID-19 mortality is controversial, and the mortality effect in sub-groups of baseline disease severity has been incompletely explored. The purpose of this study was to assess the association of RDV with mortality in patients with COVID-19. In this retrospective cohort study we compared persons receiving RDV to persons receiving best supportive care (BSC). Pat...